{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:11:40Z","timestamp":1783149100187,"version":"3.54.6"},"reference-count":91,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.resinv.2024.12.007","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T08:23:37Z","timestamp":1733991817000},"page":"96-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pneumococcal vaccines for prevention of adult pneumonia"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-9919","authenticated-orcid":false,"given":"Konosuke","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3902-4635","authenticated-orcid":false,"given":"Shingo","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.12.007_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41579-018-0001-8","article-title":"Streptococcus pneumoniae: transmission, colonization and invasion","volume":"16","author":"Weiser","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.resinv.2024.12.007_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12890-016-0242-0","article-title":"A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults","volume":"16","author":"Chalmers","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanwpc.2022.100591","article-title":"Epidemiology of pneumonia in hospitalized adults \u226518 years old in four districts of Ulaanbaatar, Mongolia, 2015\u20132019","volume":"30","author":"Fagerli","year":"2023","journal-title":"The Lancet Regional Health - Western Pacific"},{"key":"10.1016\/j.resinv.2024.12.007_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.chpulm.2023.100007","article-title":"Community-acquired pneumonia incidence in adults aged 18 Years and older in goto city, Japan A prospective population-based study","volume":"1","author":"Miyazaki","year":"2023","journal-title":"CHEST Pulmonary"},{"key":"10.1016\/j.resinv.2024.12.007_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122247","article-title":"The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study","volume":"10","author":"Morimoto","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2024.12.007_bib6","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060273","article-title":"Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques","volume":"8","author":"Said","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2024.12.007_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2018.02.007","article-title":"Burden of pneumococcal community-acquired pneumonia in adults across Europe: a literature review","volume":"137","author":"Torres","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41479-016-0008-8","article-title":"Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective","volume":"8","author":"Earle","year":"2016","journal-title":"Pneumonia"},{"key":"10.1016\/j.resinv.2024.12.007_bib10","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1017\/S0950268822001182","article-title":"Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany","volume":"150","author":"Deb","year":"2022","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.resinv.2024.12.007_bib11","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1001\/jama.1992.03490230053027","article-title":"Epidemiology of invasive pneumococcal infections in children in Finland","volume":"268","author":"Eskola","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.resinv.2024.12.007_bib12","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.vaccine.2015.05.102","article-title":"Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines","volume":"33","author":"Pilishvili","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2279394","article-title":"Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: a systematic review of published and grey literature","volume":"19","author":"Arya","year":"2023","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.resinv.2024.12.007_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged >\/=19 Years: recommendations of the advisory committee on immunization practices, United States, 2023","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.resinv.2024.12.007_bib15","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciab375","article-title":"Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults","volume":"73","author":"Isturiz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib16","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1016\/j.vaccine.2022.07.041","article-title":"Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: two multicenter observational studies from 2011 to 2020","volume":"40","author":"Maeda","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7883\/yoken.JJID.2016.311","article-title":"Serotype replacement in adult pneumococcal pneumonia after the introduction of seven-valent pneumococcal conjugate vaccines for children in Japan: a systematic literature review and pooled data analysis","volume":"70","author":"Katoh","year":"2017","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib18","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2214-109X(16)30306-0","article-title":"Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis","volume":"5","author":"Shiri","year":"2017","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.resinv.2024.12.007_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000348","article-title":"Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project","volume":"7","author":"Johnson","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib20","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1016\/j.vaccine.2011.07.097","article-title":"The immunogenicity of pneumococcal polysaccharides in infants and children: a meta-regression","volume":"29","author":"Laferriere","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib21","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","article-title":"Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales","volume":"30","author":"Andrews","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12.007","article-title":"Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in england and wales","volume":"6","author":"Djennad","year":"2018","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.resinv.2024.12.007_bib23","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1086\/516521","article-title":"Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly","volume":"176","author":"Sankilampi","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein\u2013polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2024.12.007_bib25","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1001\/jama.1992.03490230096036","article-title":"New challenges in the development of a conjugate pneumococcal vaccine","volume":"268","author":"Baltimore","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.resinv.2024.12.007_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-2478(91)90036-A","article-title":"Pneumococcal conjugate vaccines","volume":"30","author":"Peeters","year":"1991","journal-title":"Immunol Lett"},{"key":"10.1016\/j.resinv.2024.12.007_bib27","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1073\/pnas.1201964109","article-title":"Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197","volume":"109","author":"Malito","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.resinv.2024.12.007_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri2508","article-title":"B-cell responses to vaccination at the extremes of age","volume":"9","author":"Siegrist","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2024.12.007_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trivac.2016.04.004","article-title":"A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults)","volume":"5","author":"Patterson","year":"2016","journal-title":"Trials in Vaccinology"},{"key":"10.1016\/j.resinv.2024.12.007_bib30","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bm","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib31","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/IAI.66.5.2093-2098.1998","article-title":"Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants","volume":"66","author":"Dagan","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.resinv.2024.12.007_bib32","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4049\/jimmunol.161.2.702","article-title":"Carrier-induced, hapten-specific suppression: a problem of antigen presentation?","volume":"161","author":"Renjifo","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.12.007_bib33","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","article-title":"A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)","volume":"40","author":"Platt","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib35","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1001\/jama.1977.03280250039019","article-title":"Protective efficacy of pneumococcal polysaccharide vaccines","volume":"238","author":"Smit","year":"1977","journal-title":"JAMA"},{"key":"10.1016\/j.resinv.2024.12.007_bib36","first-page":"371","article-title":"Polyvalent pneumococcal polysaccharide vaccines","volume":"56","author":"Hilleman","year":"1978","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.resinv.2024.12.007_bib37","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.vaccine.2016.02.023","article-title":"Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: a systematic review and meta-analysis of randomized trials","volume":"34","author":"Diao","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib38","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1001\/archinte.1994.00420230051007","article-title":"Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials","volume":"154","author":"Fine","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib39","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.vaccine.2016.02.024","article-title":"The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis","volume":"34","author":"Kraicer-Melamed","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146338","article-title":"Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk \u2013 a systematic review and meta-analysis","volume":"11","author":"Schiffner-Rohe","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2024.12.007_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. Adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib42","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/cix549","article-title":"Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus","volume":"65","author":"Musher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib43","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1080\/21645515.2021.1923348","article-title":"Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis","volume":"17","author":"Navarro-Torn\u00e9","year":"2021","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.resinv.2024.12.007_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1473-3099(17)30049-X","article-title":"Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study","volume":"17","author":"Suzuki","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01874-17","article-title":"Accuracy of high-throughput nanofluidic PCR-based pneumococcal serotyping and quantification assays using sputum samples for diagnosing vaccine serotype pneumococcal pneumonia: analyses by composite diagnostic standards and bayesian latent class models","volume":"56","author":"Kakiuchi","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.resinv.2024.12.007_bib46","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1099\/jmm.0.071464-0","article-title":"A novel high-throughput method for molecular serotyping and serotype-specific quantification of Streptococcus pneumoniae using a nanofluidic real-time PCR system","volume":"63","author":"Dhoubhadel","year":"2014","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.resinv.2024.12.007_bib47","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJMoa022678","article-title":"Effectiveness of pneumococcal polysaccharide vaccine in older adults","volume":"348","author":"Jackson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib48","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/CVI.00064-12","article-title":"Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine","volume":"19","author":"Pride","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.resinv.2024.12.007_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003326","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study","volume":"17","author":"Lawrence","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib50","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1016\/j.vaccine.2019.04.017","article-title":"Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study","volume":"37","author":"Kim","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib51","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3390\/microorganisms10030560","article-title":"23-Valent pneumococcal polysaccharide vaccination does not prevent community-acquired pneumonia hospitalizations due to vaccine-type Streptococcus pneumoniae","volume":"10","author":"Chandler","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.resinv.2024.12.007_bib52","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/pathogens12050732","article-title":"Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults","volume":"12","author":"Farrar","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.resinv.2024.12.007_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged \u226519 Years: recommendations of the advisory committee on immunization practices, United States, 2023","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.resinv.2024.12.007_bib54","doi-asserted-by":"crossref","first-page":"e1165","DOI":"10.1542\/peds.2007-0037","article-title":"Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001\u20132005 national immunization survey","volume":"120","author":"Smith","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.resinv.2024.12.007_bib55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib56","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1016\/j.vaccine.2013.10.038","article-title":"Use of near-real-time medical claims data to generate timely vaccine coverage estimates in the US: the dynamics of PCV13 vaccine uptake","volume":"31","author":"Schuck-Paim","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib57","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jama.295.14.1668","article-title":"Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine","volume":"295","author":"Poehling","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.resinv.2024.12.007_bib58","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein\u2013polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib59","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/S0140-6736(18)33005-8","article-title":"Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study","volume":"393","author":"Hammitt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2024.12.007_bib60","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.resinv.2024.12.007_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib62","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41479-022-00097-y","article-title":"The remarkable history of pneumococcal vaccination: an ongoing challenge","volume":"14","author":"Musher","year":"2022","journal-title":"Pneumonia"},{"key":"10.1016\/j.resinv.2024.12.007_bib64","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1183\/09031936.00183614","article-title":"Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia","volume":"45","author":"Rodrigo","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.12.007_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100812","article-title":"Pneumococcal serotypes and risk factors in adult community-acquired pneumonia 2018\u201320; a multicentre UK cohort study","volume":"37","author":"Lansbury","year":"2024","journal-title":"The Lancet Regional Health - Europe"},{"key":"10.1016\/j.resinv.2024.12.007_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101271","article-title":"Non-invasive pneumococcal pneumonia due to vaccine serotypes: a systematic review and meta-analysis","volume":"44","author":"Lansbury","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.resinv.2024.12.007_bib67","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.vaccine.2019.11.026","article-title":"Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia","volume":"38","author":"Forstner","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib68","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1016\/j.vaccine.2019.05.003","article-title":"Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: a study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)","volume":"37","author":"LeBlanc","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib69","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/infdis\/jiac154","article-title":"Impact of pneumococcal conjugate vaccines on antibiotic-nonsusceptible invasive pneumococcal disease in the United States","volume":"226","author":"Bajema","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib70","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jmii.2023.07.004","article-title":"Spread of multidrug resistance in non-PCV13\/PCV20 serotypes of Streptococcus pneumoniae: a cross-sectional study ten years after the introduction of pneumococcal conjugate vaccine in Japan","volume":"56","author":"Kawaguchiya","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.resinv.2024.12.007_bib71","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1128\/AAC.03344-14","article-title":"Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States","volume":"58","author":"Richter","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2024.12.007_bib72","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1093\/cid\/ciaa043","article-title":"Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in england: a prospective observational cohort study, 2014\u20132018","volume":"71","author":"Amin-Chowdhury","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib73","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijid.2019.06.030","article-title":"Indirect effects of paediatric conjugate vaccines on invasive pneumococcal disease in older adults","volume":"86","author":"Ciruela","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib74","first-page":"906","volume":"vol. 22","author":"Mt-Isa","year":"2023"},{"key":"10.1016\/j.resinv.2024.12.007_bib75","doi-asserted-by":"crossref","first-page":"60.e9-.e29","DOI":"10.1016\/j.cmi.2015.08.027","article-title":"Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA","volume":"22","author":"Metcalf","year":"2016","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.resinv.2024.12.007_bib76","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib77","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/cid\/civ368","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children","volume":"61","author":"Olarte","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib78","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/cid\/cix310","article-title":"Childhood deaths attributable to invasive pneumococcal disease in england and wales, 2006\u20132014","volume":"65","author":"Oligbu","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib79","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1056\/NEJMoa1005384","article-title":"Bacterial meningitis in the United States, 1998\u20132007","volume":"364","author":"Thigpen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.12.007_bib80","article-title":"Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes","volume":"2","author":"Tonder","year":"2016","journal-title":"Microb Genom"},{"key":"10.1016\/j.resinv.2024.12.007_bib81","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","article-title":"Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial","volume":"23","author":"Platt","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib82","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.vaccine.2024.02.001","article-title":"Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: a phase 1 randomized controlled trial","volume":"42","author":"Borys","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib83","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(23)00572-8","article-title":"Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1\/2, double-masked, dose-finding, active-controlled, randomised clinical trial","volume":"24","author":"Wassil","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib84","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1016\/j.vaccine.2022.05.079","article-title":"Phase 1\/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years","volume":"40","author":"Chichili","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.resinv.2024.12.007_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.949469","article-title":"Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection","volume":"12","author":"Silva","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.resinv.2024.12.007_bib86","article-title":"Recent progress in pneumococcal protein vaccines","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2024.12.007_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.832254","article-title":"Pneumococcal surface proteins as virulence factors, immunogens, and conserved vaccine targets","volume":"12","author":"Aceil","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.resinv.2024.12.007_bib88","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1080\/21645515.2020.1863177","article-title":"A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States","volume":"17","author":"Fitz-Patrick","year":"2021","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.resinv.2024.12.007_bib89","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2024.12.007_bib90","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/21645515.2018.1532249","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults","volume":"15","author":"Stacey","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.resinv.2024.12.007_bib91","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41467-023-36624-8","article-title":"Optimal age targeting for pneumococcal vaccination in older adults; a modelling study","volume":"14","author":"Thindwa","year":"2023","journal-title":"Nat Commun"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:05:59Z","timestamp":1740146759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524001941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2212534524001941"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.12.007","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumococcal vaccines for prevention of adult pneumonia","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}]}}